URGCP
Up-regulator of cell proliferation
Protein Summary
May be involved in cell cycle progression through the regulation of cyclin D1 expression. May participate in the development of hepatocellular carcinoma (HCC) by promoting hepatocellular growth and survival. May play an important role in development of gastric cancer. URG4 is upregulated in the presence of hepatitis B virus (HBV)-encoded X antigen (HBxAg) and may contribute to the development of hepatocellular carcinoma by promoting hepatocellular growth and survival (Tufan et al., 2002 [PubMed 12082552]).[supplied by OMIM, Mar 2008]
- ENST00000336086
- ENSP00000336872
- ENSG00000106608
- ENST00000402306
- ENSP00000384955
- ENST00000443736
- ENSP00000392136
- ENST00000453200
- ENSP00000396918
- KIAA1507
- URG4
- URG4
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.92 | ||
interacting protein | 0.85 | ||
transcription factor binding site profile | 0.78 | ||
molecular function | 0.73 | ||
cell line | 0.6 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 29.73 (req: < 5)
Gene RIFs: 24 (req: <= 3)
Antibodies: 157 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 29.73 (req: >= 5)
Gene RIFs: 24 (req: > 3)
Antibodies: 157 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0